SCHEMBL7676850

SCHEMBL7676850

CCOC(=O)C(C)c1cc(C)c(C(=O)c2ccc(OC)c(OC)c2)n1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.48
TSHR P16473 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
ALDH1A1 P00352 5/20 0.46
POLB P06746 1/20 0.46
PDK1 Q15118 1/20 0.44
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
SIRT3 Q9NTG7 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7681002 0.89 TSHR (0.51) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7681736 0.84 PTGS2 (0.45) TSHRCYP1A2ALDH1A1MAPTKDM4E
SCHEMBL7680326 0.83 MEN1 (0.44) CYP3A4ALDH1A1MAPTKDM4EHPGD
SCHEMBL7676839 0.82 ABCB11 (0.43) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7678100 0.82 ABCB11 (0.58) CYP2C19TSHRCYP1A2CYP2C9ALDH1A1
SCHEMBL7684691 0.82 CYP2C19 (0.46) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7682285 0.79 ABCB11 (0.49) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7676984 0.79 ABCB11 (0.41) TSHRCYP1A2ALDH1A1POLBPPARG
SCHEMBL7681969 0.79 ABCB11 (0.41) TSHRCYP1A2ALDH1A1MAPTKDM4E
SCHEMBL7680795 0.79 ABCB11 (0.44) TSHRCYP1A2ALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A CYP2C19 4174/4885TSHR 2892/4885CYP1A2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.